Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation

Exclusion Criteria

• •1. Any medical or psychological condition that may prevent the study participation, based on practitioners' decision-making.
• •2. Participation in an ongoing clinical trial.
• •3. Known or suspected severe hypersensitivity for secukinumab, formulation excipients, or injection device components (i.e., latex).
• •4. Clinically significant infection exacerbation, including active tuberculosis.
• •5. Patients with active inflammatory bowel disease (IBD).
• •6. Age \<18 years.
• •7. Pregnancy and breastfeeding.
• •8. Patients who received any vaccine within 4 weeks prior to secukinumab initiation.